• 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events
• 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
• A case of Quebec platelet disorder with interstitial pneumonia
• A Comprehensive Review of Congenital Platelet Disorders, Thrombocytopenias and Thrombocytopathies
• Abnormal differentiation of B cells and megakaryocytes in patients with Roifman syndrome
• Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade
• Androgen therapy in inherited bone marrow failure syndromes: analysis from the Canadian Inherited Marrow Failure Registry
• Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets
• Bleeding risks associated with inheritance of the Quebec platelet disorder
• Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review
• Breaking barriers: Quebec platelet disorder
• Challenges in diagnosis of von Willebrand disease in the presence of combined mutations of different genes
• Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia
• Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis
• Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
• Current Strategies in Diagnosis of Inherited Storage Pool Defects
• Diagnosis and Management of Acquired von Willebrand Disease in Heart Disease: A Review of the Literature
• Diagnostic assessment of platelet disorders: what are the challenges to standardization?
• Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use
• Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature
• Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial
• Enhancer-gene rewiring in the pathogenesis of Quebec platelet disorder
• Erratum: Quebec Platelet Disorder: Update on Pathogenesis, Diagnosis, and Treatment
• Evaluation of urokinase plasminogen activator in urine from individuals with Quebec platelet disorder
• Evolution and Impact of Thrombocytopenia in Septic Shock: A Retrospective Cohort Study
• Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
• Extreme thrombocytosis in low-risk essential thrombocythemia: Retrospective review of vascular events and treatment strategies
• False-Positive Syphilis Serologies in a Woman Receiving Intravenous Immunoglobulin
• Fibrinolysis and bleeding of unknown cause
• Genetic abnormalities in biopsy-proven, adult-onset hemolytic uremic syndrome and C3 glomerulopathy
• Genotypic analysis of a large cohort of patients with suspected atypical hemolytic uremic syndrome
• Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies
• High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML
• Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
• Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry&quo
• Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia
• Impaired platelet procoagulant mechanisms in patients with bleeding disorders
• Improved platelet counts during prolonged tranexamic therapy for Quebec platelet disorder implicate the underlying fibrinolytic defect as the cause of lower platelet counts
• Improving blood disorder diagnosis: reflections on the challenges
• Incidence and risk factors for severe preeclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia at preterm and term gestation: a population-based study
• Incidence of thrombotic microangiopathies in Quebec: insight from a laboratory centralizing ADAMTS-13 testing
• Increased expression of urokinase plasminogen activator in Quebec platelet disorder is linked to megakaryocyte differentiation
• Inherited disorders of platelet alpha-granules
• Inherited disorders of the fibrinolytic pathway
• Inherited Kidney Complement Diseases
• Inherited trombophilic states and pulmonary embolism
• Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysis
• Intracellular activation of the fibrinolytic cascade in the Quebec Platelet Disorder
• Laboratory testing for bleeding disorders: strategic uses of high and low-yield tests
• Live imaging of platelets and neutrophils during antibody-mediated neurovascular thrombosis
• Long term follow-up of pediatric-onset Evans syndrome: broad immunopathological manifestations and high treatment burden
• Long VITT: A case report
• Management of a Left Atrial Appendage Thrombus Due to Atrial Fibrillation Complicating Quebec Platelet Disorder
• Management of Quebec Platelet Disorder for Cervical Facet Injections in the Outpatient Setting: A Case Report
• Monoclonal gammopathy-associated thrombotic microangiopathy
• Neurological Involvement in Childhood Evans Syndrome
• Origins of oscillation patterns in cyclical thrombocytopenia
• Pathology of Gastrointestinal and Liver Complications of Hematopoietic Stem Cell Transplantation
• Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale
• Persistence of Platelets Activation Prior to Second Doses of Covid-19 Vaccine After Vaccine-Induced Immune Thrombotic Thrombocytopenia
• Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair: a case report
• Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene
• Pharmacodynamics of romiplostim alone and in combination with pegfilgrastim on acute radiation-induced thrombocytopenia and neutropenia in non-human primates
• Physician decision making in selection of second-line treatments in immune thrombocytopenia in children
• Platelet abnormalities in Huntington's disease
• Platelet factor V New York: a defect in factor V distinct from that in factor V Quebec resulting in impaired prothrombinase generation
• Platelet-delivered therapeutics
• Platelet-derived extracellular vesicles in Huntington's disease
• Platelets from patients with the Quebec platelet disorder contain and secrete abnormal amounts of urokinase-type plasminogen activator
• Predicting Adverse Outcomes for Shiga Toxin-Producing Escherichia coli Infections in Emergency Departments
• Predicting Hemolytic Uremic Syndrome and Renal Replacement Therapy in Shiga Toxin-producing Escherichia coli-infected Children
• Proteomics applied to the study of platelet-related diseases: aiding the discovery of novel platelet biomarkers and drug targets
• Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia
• Quebec platelet disorder
• Quebec platelet disorder
• Quebec platelet disorder is linked to the urokinase plasminogen activator gene (PLAU) and increases expression of the linked allele in megakaryocytes
• Quebec platelet disorder: features, pathogenesis and treatment
• Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment
• Rare inherited coagulation and fibrinolytic defects that challenge diagnostic laboratories
• Refractory immune TTP following Pfizer-BioNTech COVID-19 vaccine successfully salvaged with caplacizumab
• Renal Thrombotic Microangiopathy: A Review
• Reported prevalence of von Willebrand disease worldwide in relation to income classification
• Residual risks of bacterial contamination for pathogen-reduced platelet components
• Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group
• Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes
• Simultaneous measurement of adenosine triphosphate release and aggregation potentiates human platelet aggregation responses for some subjects, including persons with Quebec platelet disorder
• Site-specific venous thrombosis in essential thrombocythemia: Impact on subsequent vascular events and survival
• Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT): COMMENT from Roberge, et al
• The duplication mutation of Quebec platelet disorder dysregulates PLAU, but not C10orf55, selectively increasing production of normal PLAU transcripts by megakaryocytes but not granulocytes
• The value of proteomics for the diagnosis of a platelet-related bleeding disorder
• Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia
• Thrombin generation abnormalities in Quebec platelet disorder
• Thrombocytopenia and neonatal outcomes among extremely premature infants exposed to maternal hypertension
• Thrombopoietin levels in Quebec platelet disorder-Implications for the mechanism of thrombocytopenia
• Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin
• Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination; a systematic review
• Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
• Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial
• Von Willebrand Disease: Gaining a global perspective
• Young platelet millionaires with essential thrombocythemia